|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
|
OA12118A
(en)
|
1999-12-10 |
2006-05-04 |
Pfizer Prod Inc |
PyrroloÄ2,3-dÜpyrimidine compounds.
|
|
OA12292A
(en)
*
|
2000-06-26 |
2003-11-11 |
Pfizer Prod Inc |
PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents.
|
|
PY0228255A
(es)
|
2001-12-06 |
2004-06-01 |
Pfizer Prod Inc |
Compuestos cristalinos novedosos
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
IL166241A0
(en)
|
2002-07-29 |
2006-01-15 |
Rigel Pharmaceuticals Inc |
Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
|
|
ATE402700T1
(de)
*
|
2002-08-27 |
2008-08-15 |
Merck Patent Gmbh |
Glycinamid-derivate als raf-kinase-hemmer
|
|
WO2004047843A1
(en)
|
2002-11-26 |
2004-06-10 |
Pfizer Products Inc. |
Method of treatment of transplant rejection
|
|
ES2421139T3
(es)
|
2003-07-30 |
2013-08-29 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
|
|
WO2005105146A1
(en)
*
|
2004-05-03 |
2005-11-10 |
Novartis Ag |
Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
|
|
MXPA06015237A
(es)
|
2004-06-29 |
2007-12-10 |
Amgen Inc |
Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
|
|
MX2007001399A
(es)
|
2004-08-02 |
2007-04-18 |
Osi Pharm Inc |
Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas.
|
|
RU2007123675A
(ru)
*
|
2004-11-24 |
2008-12-27 |
Новартис АГ (CH) |
Комбинации ингибиторов jak
|
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
JP5071374B2
(ja)
|
2005-07-14 |
2012-11-14 |
アステラス製薬株式会社 |
ヘテロ環ヤヌスキナーゼ３阻害剤
|
|
CN102127078A
(zh)
|
2005-07-14 |
2011-07-20 |
安斯泰来制药株式会社 |
Janus激酶3的杂环类抑制剂
|
|
WO2007012953A2
(en)
|
2005-07-29 |
2007-02-01 |
Pfizer Products Inc. |
Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
|
|
WO2007038215A1
(en)
|
2005-09-22 |
2007-04-05 |
Incyte Corporation |
Tetracyclic inhibitors of janus kinases
|
|
HUE028588T2
(hu)
|
2005-12-13 |
2016-12-28 |
Incyte Holdings Corp |
Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
|
|
WO2007098507A2
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
GB0605691D0
(en)
*
|
2006-03-21 |
2006-05-03 |
Novartis Ag |
Organic Compounds
|
|
ES2415863T3
(es)
|
2006-12-22 |
2013-07-29 |
Incyte Corporation |
Heterociclos sustituidos como inhibidores de Janus Quinasas
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
EP2740731B1
(en)
|
2007-06-13 |
2016-03-23 |
Incyte Holdings Corporation |
Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
|
WO2009007839A1
(en)
*
|
2007-07-11 |
2009-01-15 |
Pfizer Inc. |
Pharmaceutical compositions and methods of treating dry eye disorders
|
|
HRP20170317T1
(hr)
|
2008-02-15 |
2017-04-21 |
Rigel Pharmaceuticals, Inc. |
Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
|
|
MY165582A
(en)
|
2008-03-11 |
2018-04-05 |
Incyte Holdings Corp |
Azetidine and cyclobutane derivatives as jak inhibitors
|
|
US8063058B2
(en)
|
2008-04-16 |
2011-11-22 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk and JAK protein kinases
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
BRPI0910668A2
(pt)
|
2008-04-22 |
2019-09-24 |
Portola Pharmaceutiacals Inc |
inibidores de proteína quinases
|
|
RU2011105768A
(ru)
*
|
2008-08-01 |
2012-09-10 |
Биокрист Фармасьютикалз, Инк. (Us) |
Производные пиперидина в качестве ингибиторов jakз
|
|
RS53382B
(sr)
*
|
2008-08-20 |
2014-10-31 |
Zoetis Llc |
Jedinjenja pirol [2,3-d]pirimidina
|
|
EP2396004A4
(en)
*
|
2009-02-11 |
2012-07-25 |
Reaction Biology Corp |
SELECTIVE KINASE HEMMER
|
|
CA2759026C
(en)
|
2009-04-20 |
2019-01-15 |
Auspex Pharmaceuticals, Inc. |
Piperidine inhibitors of janus kinase 3
|
|
BRPI1012108B8
(pt)
|
2009-05-22 |
2021-05-25 |
Incyte Corp |
composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
|
|
NZ596479A
(en)
|
2009-05-22 |
2014-01-31 |
Incyte Corp |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
MX2012002641A
(es)
*
|
2009-09-10 |
2012-03-14 |
Hoffmann La Roche |
Inhibidores de cinasa janus (jak).
|
|
EA021478B1
(ru)
|
2009-10-09 |
2015-06-30 |
Инсайт Корпорейшн |
ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
|
|
AU2010308028A1
(en)
|
2009-10-15 |
2012-04-19 |
Pfizer Inc. |
Pyrrolo[2,3-d] pyrimidine compounds
|
|
CA2782720A1
(en)
|
2009-12-18 |
2011-06-23 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
CN102712640A
(zh)
*
|
2010-01-12 |
2012-10-03 |
弗·哈夫曼-拉罗切有限公司 |
三环杂环化合物、其组合物和应用方法
|
|
AU2011213198B2
(en)
|
2010-02-05 |
2014-04-24 |
Zoetis Llc |
Pyrrolo [ 2,3-d] pyrimidine urea compounds as JAK inhibitors
|
|
CA2792508C
(en)
|
2010-03-10 |
2018-01-16 |
Incyte Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
EA202091303A3
(ru)
|
2010-05-21 |
2021-05-31 |
Инсайт Холдингс Корпорейшн |
Композиция ингибитора jak для местного применения
|
|
EP2975027A1
(en)
|
2010-11-01 |
2016-01-20 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
|
CA2818542A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
ES2536415T3
(es)
|
2010-11-19 |
2015-05-25 |
Incyte Corporation |
Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
|
|
EP2481397A1
(en)
|
2011-01-27 |
2012-08-01 |
Ratiopharm GmbH |
Pharmaceutical compositions comprising tasocitinib
|
|
EP2481411A1
(en)
|
2011-01-27 |
2012-08-01 |
Ratiopharm GmbH |
Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
|
|
WO2012112847A1
(en)
|
2011-02-18 |
2012-08-23 |
Novartis Pharma Ag |
mTOR/JAK INHIBITOR COMBINATION THERAPY
|
|
EP2691395B1
(en)
|
2011-03-28 |
2017-08-30 |
ratiopharm GmbH |
Processes for preparing tofacitinib salts
|
|
US9050342B2
(en)
|
2011-03-29 |
2015-06-09 |
Pfizer Inc. |
Beneficial effects of combination therapy on cholesterol
|
|
CN103459394B
(zh)
*
|
2011-04-08 |
2016-04-27 |
辉瑞大药厂 |
结晶和非结晶形式的托法替尼，以及包含托法替尼和渗透增强剂的药物组合物
|
|
ES2414384T3
(es)
|
2011-05-11 |
2013-07-19 |
Ratiopharm Gmbh |
Composición de liberación modificada que comprende ranolazina
|
|
US8691807B2
(en)
|
2011-06-20 |
2014-04-08 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
|
|
WO2013023119A1
(en)
|
2011-08-10 |
2013-02-14 |
Novartis Pharma Ag |
JAK P13K/mTOR COMBINATION THERAPY
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
EP2782579B1
(en)
|
2011-11-23 |
2019-01-02 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
|
US10821111B2
(en)
|
2011-11-30 |
2020-11-03 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
|
US9089574B2
(en)
*
|
2011-11-30 |
2015-07-28 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
|
WO2013090490A1
(en)
|
2011-12-15 |
2013-06-20 |
Ratiopharm Gmbh |
Tofacitinib salts
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
WO2014016338A1
(en)
|
2012-07-25 |
2014-01-30 |
Lek Pharmaceuticals D.D. |
New synthetic route for the preparation of 3-amino-piperidine compounds
|
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
KR102242077B1
(ko)
|
2012-11-15 |
2021-04-20 |
인사이트 홀딩스 코포레이션 |
룩솔리티니브의 서방성 제형
|
|
CN104955803B
(zh)
*
|
2012-11-30 |
2017-11-28 |
斯洛文尼亚莱柯制药股份有限公司 |
通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物
|
|
EP2935216B1
(en)
|
2012-12-17 |
2018-06-27 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of tofacitinib and intermediates thereof
|
|
EP2938616A4
(en)
|
2012-12-28 |
2016-06-15 |
Glenmark Pharmaceuticals Ltd |
PROCESSING METHOD FOR THE PRODUCTION OF TOFACITINIB AND INTERMEDIATE PRODUCTS THEREOF
|
|
EA027879B1
(ru)
|
2013-02-22 |
2017-09-29 |
Пфайзер Инк. |
ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
|
|
EP3489239B1
(en)
|
2013-03-06 |
2021-09-15 |
Incyte Holdings Corporation |
Processes and intermediates for making a jak inhibitor
|
|
JP6041823B2
(ja)
|
2013-03-16 |
2016-12-14 |
ファイザー・インク |
トファシチニブの経口持続放出剤形
|
|
US20140343034A1
(en)
|
2013-04-25 |
2014-11-20 |
Japan Tobacco Inc. |
Skin barrier function improving agent
|
|
WO2014174073A1
(en)
|
2013-04-26 |
2014-10-30 |
Sandoz Ag |
Sustained release formulations of tofacitinib
|
|
MX376856B
(es)
|
2013-08-07 |
2025-03-07 |
Incyte Holdings Corp |
Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
|
|
CN104513248B
(zh)
*
|
2013-09-30 |
2019-05-24 |
重庆医药工业研究院有限责任公司 |
一种托法替尼中间体的纯化方法
|
|
LT3077395T
(lt)
|
2013-12-05 |
2018-02-12 |
Pfizer Inc. |
Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
|
|
ES2865058T3
(es)
|
2013-12-09 |
2021-10-14 |
Unichem Lab Ltd |
Un proceso mejorado para la preparación de (3R,4R)-(1-bencil-4-metilpiperidin-3-il)-metilamina
|
|
CA2881262A1
(en)
|
2014-02-06 |
2015-08-06 |
Prabhudas Bodhuri |
Solid forms of tofacitinib salts
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
WO2016024185A1
(en)
|
2014-08-12 |
2016-02-18 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
|
|
ES2962330T3
(es)
|
2015-01-20 |
2024-03-18 |
Wuxi Fortune Pharmaceutical Co Ltd |
Inhibidor de jak
|
|
JP6687596B2
(ja)
*
|
2015-02-17 |
2020-04-22 |
アモーレパシフィック コーポレーションＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｎ−［４−（１−アミノエチル）−フェニル］−スルホンアミド誘導体のキラル分割方法
|
|
CN104761556B
(zh)
*
|
2015-03-21 |
2017-06-23 |
河北国龙制药有限公司 |
托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法
|
|
EP3078665A1
(en)
|
2015-04-10 |
2016-10-12 |
OLON S.p.A. |
Efficient method for the preparation of tofacitinib citrate
|
|
EP3290418B1
(en)
|
2015-04-29 |
2019-05-15 |
Wuxi Fortune Pharmaceutical Co., Ltd |
Janus kinase (jak) inhibitors
|
|
CA2984183C
(en)
|
2015-05-01 |
2021-11-09 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
|
|
DK3305788T3
(da)
|
2015-05-29 |
2020-09-28 |
Wuxi Fortune Pharmaceutical Co Ltd |
Janus-kinase-hæmmer
|
|
BR112017013253A2
(pt)
*
|
2015-07-27 |
2018-02-27 |
Unichem Laboratories Limited |
comprimidos de desintegração oral, processo para produzir comprimido de desintegração oral contendo tofacitinibe ou seus sais farmaceuticamente aceitáveis, processo para produzir comprimido de desintegração oral, desintegrante, e edulcorantes
|
|
KR101771219B1
(ko)
*
|
2015-08-21 |
2017-09-05 |
양지화학 주식회사 |
야누스 키나제 1 선택적 억제제 및 그 의약 용도
|
|
CN108472298B
(zh)
|
2015-11-24 |
2021-04-20 |
深圳阿拉丁医疗科技有限公司 |
选择性激酶抑制剂
|
|
CN105348287A
(zh)
*
|
2015-11-30 |
2016-02-24 |
宁波立华制药有限公司 |
一种枸橼酸托法替布的新型合成工艺
|
|
KR102565407B1
(ko)
*
|
2016-01-04 |
2023-08-10 |
(주)아모레퍼시픽 |
극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
|
|
WO2017125417A1
(en)
|
2016-01-18 |
2017-07-27 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Tofacitinib as vaccination immune modulator
|
|
RU2714206C1
(ru)
|
2016-06-30 |
2020-02-13 |
Даевунг Фармасьютикал Ко., Лтд. |
Пиразолопиримидиновые производные в качестве ингибитора киназы
|
|
CN106831538B
(zh)
*
|
2017-01-22 |
2019-06-25 |
苏州楚凯药业有限公司 |
托法替尼中间体的制备方法
|
|
KR102398659B1
(ko)
|
2017-03-17 |
2022-05-16 |
주식회사 대웅제약 |
카이네이즈 저해제로서의 피롤로트리아진 유도체
|
|
CN107602569A
(zh)
*
|
2017-10-23 |
2018-01-19 |
上海博悦生物科技有限公司 |
一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
|
|
KR102078805B1
(ko)
|
2017-11-30 |
2020-02-19 |
보령제약 주식회사 |
토파시티닙을 포함하는 약제학적 조성물
|
|
TW201924683A
(zh)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
用於治療骨髓增生性贅瘤的低劑量組合療法
|
|
MA51431B1
(fr)
|
2017-12-28 |
2022-08-31 |
Daewoong Pharmaceutical Co Ltd |
Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
|
|
KR102577242B1
(ko)
|
2017-12-28 |
2023-09-11 |
주식회사 대웅제약 |
카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
|
|
KR102577241B1
(ko)
|
2017-12-28 |
2023-09-11 |
주식회사 대웅제약 |
카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
|
|
MD3746429T2
(ro)
|
2018-01-30 |
2022-08-31 |
Incyte Corp |
Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
|
|
US12161748B2
(en)
|
2018-01-31 |
2024-12-10 |
Twi Biotechnology, Inc. |
Topical formulations comprising tofacitinib
|
|
JP7324210B2
(ja)
*
|
2018-01-31 |
2023-08-09 |
ティダブリューアイ・バイオテクノロジー・インコーポレイテッド |
トファシチニブを含む局所製剤
|
|
KR20260080448A
(ko)
|
2018-03-30 |
2026-06-02 |
인사이트 코포레이션 |
Jak 억제제를 사용하는 화농성 한선염의 치료
|
|
KR102131107B1
(ko)
|
2019-01-15 |
2020-07-07 |
주식회사 다산제약 |
3-아미노-피페리딘 화합물의 신규한 제조 방법
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
GB2596942B
(en)
|
2019-02-27 |
2023-05-10 |
Samson Clinical Pty Ltd |
Tofacitinib via oral mucosa for use in treatment of autoimmune hair loss or excessing hair shedding
|
|
CA3132109A1
(en)
|
2019-03-13 |
2020-09-17 |
Intas Pharmaceuticals Ltd. |
Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
|
|
EP3946606B1
(en)
|
2019-03-27 |
2025-01-01 |
Insilico Medicine IP Limited |
Bicyclic jak inhibitors and uses thereof
|
|
KR102890724B1
(ko)
*
|
2019-04-05 |
2025-11-25 |
주식회사유한양행 |
(3r,4r)-1-벤질-n,4-디메틸피페리딘-3-아민 또는 이의 염의 제조방법 및 이를 이용한 토파시티닙의 제조방법
|
|
KR102897231B1
(ko)
|
2019-10-31 |
2025-12-05 |
아르티 인더스트리스 리미티드 |
토파시티닙 및 그 중간체의 제조방법
|
|
EP4054527A4
(en)
|
2019-11-08 |
2023-12-06 |
Cage Bio Inc. |
TOPICAL ADMINISTRATION OF TOFACITINIB USING IONIC LIQUID
|
|
EP4057989A1
(en)
|
2019-11-14 |
2022-09-21 |
Pfizer Inc. |
1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
|
|
KR102877132B1
(ko)
*
|
2019-11-25 |
2025-10-27 |
주식회사 대웅제약 |
신규한 트리아졸로피리딘 유도체 및 이를 포함하는 약학 조성물
|
|
BR112022020020A2
(pt)
|
2020-04-04 |
2022-11-22 |
Pfizer |
Métodos de tratamento da doença do coronavírus 2019
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
WO2022194782A1
(en)
*
|
2021-03-15 |
2022-09-22 |
Chiesi Farmaceutici S.P.A. |
Heterocyclic derivatives as janus kinase inhibitors
|
|
CN113549075B
(zh)
*
|
2021-06-23 |
2025-09-23 |
合肥华方医药科技有限公司 |
一种枸橼酸托法替布非对映异构体杂质的合成方法
|
|
EP4180042A1
(en)
|
2021-11-15 |
2023-05-17 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A film coated tablet comprising micronized tofacitinib
|
|
CN122341609A
(zh)
|
2023-12-05 |
2026-07-03 |
株式会社大熊制药 |
1-((3S,4R)-3-((2-((1-乙基-1H-吡唑-4-基)氨基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)-4-氟哌啶-1-基)丙-2-烯-1-酮的制备方法及其中间体化合物
|